Prospective randomized human trials, crossover pharmacokinetic studies, and ClinicalTrials.gov interventional readouts with direct participant sample sizes (N). Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Data will be analysed using linear mixed models (LMM) to evaluate the effects of method, period, and sequence while accounting for the cluster-based design. Missing data will be handled via Full Information Maximum Likelihood (FIML).
Eight sessions of TENS and DDC, combined with conventional physical therapy, including Kegel and breathing exercises, can reduce OAB symptoms and improve QOL in subjects with OAB syndrome. Diadynamic current can be used as an adjunct to conventional TENS in TTNS for treating OAB syndrome.
EO-PBMT was associated with lower cumulative OM occurrence, shorter application time, and good tolerability, supporting its use as a promising, less burdensome preventive strategy in pediatric oncology.
All the treatments were well tolerated overall.
Insulin needs decrease rapidly upon initiation of semaglutide use in type 1 diabetes on pump therapy, predominantly due to bolus changes from less carbohydrate consumption.
Further long-term, large-scale studies are recommended to confirm this evidence.
This project will generate evidence on the effects of nicotine concentration and source claims on ONP packaging in young adults who are not using but susceptible to tobacco, young adults using tobacco, and adults using tobacco to inform potential regulations.
This study suggests that lumateperone can be considered an effective and safe adjuvant treatment for MDD.
In women with obesity and PCOS, semaglutide improved an overall taste recognition score, altered RNA expression in the tongue and modified brain activity in response to sweet and savory food cues and to tasting sweet solution.
Preliminary findings suggest that the mental health benefits of chronic RET were independent of placebo effects, notwithstanding the potential limitations of small sample size and the non-mode-specific measure of expectations.
Venlafaxine ER has a favorable benefit-risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without...
In patients with COMISA, the combination of eszopiclone with BBTI resulted in comparable improvement in sleep quality of life to that achieved with BBTI-only therapy.
Amlitelimab treatment led to clinically meaningful improvements in COAs by Week 24 versus placebo.
Applied to the skin GT20029 demonstrated significant efficacy in hair regrowth with good tolerability.
These findings suggest that PBMt may enhance MIN therapy for FPHL, particularly in reducing telogen-phase hair counts within a shorter treatment period.
In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated.
This trial explored the feasibility of following plaque inflammation with PET-MRI using [ 18 F]FDG and [ 68 Ga]DOTATATE.
The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit beyond adiposity reduction.
The novel nutraceutical combination of Estro-G100 and GABA may help support women during menopause.
TRT increased circulating neutrophils and monocytes and decreased lymphocytes and platelets in men with hypogonadism.
When comparing the two treatment groups, PPAR-γ and ADIPO expression were significantly higher in the Met + EZY group during T2 and T3 compared to the Met group (p < 0.001).
The observed associations could be consistent with the constitutive activation of the GLP-1R in the presence of this variant with reduced activation/signaling in response to pharmacologic agents, a pattern that has been...
Conclusions : BA-2591 was safe and demonstrated modest, adjunctive benefits for fasting glycemia and immunologic profiles over 6 weeks, without changes in body weight or fat mass.
Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable.
Intraoperative follicle immersion and postoperative applied to the skin application of rb-bFGF significantly enhance graft survival, reduce early hair loss, decrease complications, and.
The results for sertraline confirm the assay sensitivity of the trial.
Rosuvastatin single-drug treatment does not appear to increase the risk of arrhythmia.
Wb-BDNF reflects the total blood BDNF pool and avoids platelet aggregation-related confounds seen in s-BDNF measures.
PYY1875 showed modest efficacy as an add-on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
The significant changes in FBS from baseline to week 12 were - 23.1, -16.15, and - 15.25 mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
